ERBB3 and cancer: Studies have shown that monoclonal HER3 antibody MM121 which targets ligand-dependent HER3 activation [131] exhibits substantial tumor growth arrest against various xenograft tumors including prostate (DU-145), ovarian (OVCAR-8) and renal (ACHN) cancer [131-133], albeit without inducing complete tumor regression.